Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Zyppah's anti-snoring mouthpiece is FDA-cleared and clinically proven with a 91% success rate in stopping snoring according to published clinical trials. The product combines mandibular advancement and a patented tongue-stabilization feature. Over 400,000 customers have used the device, generating $55M+ in sales. The company claims an 85% gross profit margin and less than a 7% return rate. Clinical results show high efficacy compared to competitors (15–45%), with safety confirmed by biocompatibility testing under ISO 10993 standards. The company has expanded its offerings with related products such as mouth tape for nasal breathing enhancement. NBA Hall of Famer Shaquille O’Neal serves as global brand ambassador. Zyppah also operates Sleep Certified®, a referral network connecting patients with trained dentists/physicians for customized sleep solutions. Five Snore Expert Centers in California provide diagnosis/treatment services; headquarters are in Reno, NV; business operations also listed in Calabasas, CA.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Zyppah.